Biltstraat 106

3572 BJ, Utrecht, the Netherlands

info@virology-education.com

  • White Twitter Icon
  • White LinkedIn Icon
  • White Facebook Icon

Tel: +31 (0)30 230 7140

© 2020 by Virology Education

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs - Enduring Materials

Enduring Materials

Session 1 - 20 Years in Review

Drug-drug interactions: all you need to know beyond www.hiv-druginteractions.org

Marta Boffito, MD, PhD

Chelsea and Westminster Hospital, United Kingdom

button_slides.png

Enduring Materials

Session 1 - 20 Years in Review

Stop measuring ARV levels in plasma!

Courtney Fletcher, PharmD

University of Nebraska, United States

Enduring Materials

Session 1 - 20 Years in Review

50% adherence is enough with modern ARVs, right?

Terrence Blaschke, MD

Stanford University, United States

button_slides.png
button_video.png

Enduring Materials

Session 1 - 20 Years in Review

Modern ARVs do not develop resistance, do they?

Jonathan Schapiro, MD

Sheba Medical Center, Israel

Enduring Materials

Session 2 - Novel strategies for prevention and therapy

The ‘third wave’ of TB drug development: what’s on the horizon (for patients with or without HIV)

Kelly Dooley, MD, PhD

Johns Hopkins University, United States

button_slides.png
button_video.png

Enduring Materials

Session 2 - Novel strategies for prevention and therapy

ABSTRACT

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine

Anthony Podany, PharmD

University of Nebraska Medical Center, United States

button_slides.png

Enduring Materials

Session 2 - Novel strategies for prevention and therapy

ABSTRACT

In silico design of a microarray patch as a multipurpose prevention technology

Rajith Rajoli

Univerisity Of Liverpool, United Kingdom

button_slides.png

Enduring Materials

Session 2 - Novel strategies for prevention and therapy

ABSTRACT

Population pharmacokinetics of VRC01 in infants and adults

Jerry Li

University of California San Diego, United States

button_slides.png

Enduring Materials

Session 2 - Novel strategies for prevention and therapy

ABSTRACT

The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects

Samit Joshi, MD

ViiV Healthcare, United States

button_slides.png

Enduring Materials

Session 3 - Viral Hepatitis & Liver Disease

Novel antiviral and immune targets to cure HBV

Fabien Zoulim, MD

INSERM, France

button_slides.png
button_video.png

Enduring Materials

Session 3 - Viral Hepatitis & Liver Disease

Pharmacological treatment of NASH

Sven Francque, MD, PhD

University Hospital Antwerp & University of Antwerp, Belgium

button_slides.png
button_video.png

Enduring Materials

Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare

Improved long acting drug delivery: What are the technologies?

Andrew Owen, BSc, MSc, PhD, FSB

University of Liverpool, United Kingdom

button_slides.png
button_video.png

Enduring Materials

Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare

Long acting HIV drugs for treatment: Data and potential implementation

Charles Flexner, MD

Johns Hopkins University, United States

button_slides.png
button_video.png

Enduring Materials

Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare

Long Acting HIV Drugs for Prevention: Data and Potential implementation

Laura Waters, MD

Central & North West London NHS Trust, Mortimer Market Centre, United Kingdom

button_slides.png
button_video.png

Enduring Materials

Session 4 - Drug-drug interactions: evolving challenges

Clinical Case Presentation

Catia Marzolini, PharmD, PhD

University Hospital Basel & University of Liverpool

button_slides.png
button_video.png

Enduring Materials

Session 4 - Drug-drug interactions: evolving challenges

ClinicalCasesDDI Website Launch

José Moltó, MD, PhD

Hospital Universitari Germans Trias i Pujol, Spain

Enduring Materials

Session 4 - Drug-drug interactions: evolving challenges

ABSTRACT

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Sara Gibbons

University of Liverpool, United Kingdom

button_slides.png

Enduring Materials

Session 4 - Drug-drug interactions: evolving challenges

ABSTRACT

Drugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction

Tess Martin

APHM La Timone, France

button_slides.png

Enduring Materials

Session 4 - Drug-drug interactions: evolving challenges

ABSTRACT

Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy

Michelle Pham

University Of Nebraska Medical Center

button_slides.png

Enduring Materials

Debate: Dual maintenance for HIV: Why fix it if it's not broken?

Pro Perspective

José Ramón Arribas, MD

Hospital La Paz, IdiPaz, Spain

button_slides.png
button_video.png

Enduring Materials

Debate: Dual maintenance for HIV: Why fix it if it's not broken?

Con Perspective

Andrew Hill, MD

University of Liverpool, United Kingdom

button_slides.png
button_video.png

Enduring Materials

Debate: Dual maintenance for HIV: Why fix it if it's not broken?

Debate

button_video.png

Enduring Materials

Special Lecture

Regulatory perspective on evaluating ARVs in during pregnancy

Kimberly Struble, PharmD

US Food & Drug Administration, United States

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Special Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)

Paul Domanico, PhD

Clinton Health Access Initiative, United States

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1

Laura Dickinson

University Of Liverpool, United Kingdom

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum

Jeremiah Momper

University Of California San Diego, United States

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment

Marije Van Schalkwyk, MD

Stellenbosch University, South Africa

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum

Kristina Brooks, PharmD

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy

Jenna Yager

University of Colorado, United States

button_slides.png

Enduring Materials

Session 5 - Special populations and adherence

ABSTRACT

An exploration of adherence measures to detect recent changes in Truvada® dosing patterns

Daijha Anderson

University Of North Carolina Eshelman School Of Pharmacy, United States

button_slides.png

Enduring Materials

Short Poster Presentations; "Best of Posters"

ABSTRACT

Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV

Felix Stader

University Hospital Basel, Switzerland

button_slides.png

Enduring Materials

Short Poster Presentations; "Best of Posters"

ABSTRACT

Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy

Mary Gockenbach

US Food and Drug Administration, Division of Pediatrics and Maternal Health

button_slides.png

Enduring Materials

Short Poster Presentations; "Best of Posters"

ABSTRACT

A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents

Bernard Ngara

University Of Zimbabwe College Of Health Sciences, Zimbabwe

Enduring Materials

Short Poster Presentations; "Best of Posters"

ABSTRACT

Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir

Aarti Patel

Glaxosmithkline R&D, United Kingdom

button_slides.png

Enduring Materials

The Next 20 Years

CRISPR/Cas and gene editing for HIV

Paula Cannon, PhD

University of Southern California Keck School of Medicine, United States

button_slides.png
button_video.png

Enduring Materials

The Next 20 Years

Understanding the key determinants of performance for long-acting formulations

Andrew Owen, BSc, MSc, PhD, FSB

University of Liverpool, United Kingdom